本帖最后由 老马 于 2012-1-13 21:20 编辑 + v( F0 G5 O& z7 K
, F( C) z+ n4 h* `爱必妥和阿瓦斯丁的比较
! ?# U* \) z) R
$ @+ ^, t$ ?8 u9 o
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
& Q; g ~3 S; Z B
+ D/ @" n- K4 c2 a4 R, s6 A
" s/ m& }6 [+ J K( X; n: W6 Zhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/1 F$ _4 u7 S9 D. U3 T& @
==================================================& U6 c/ f' _% X* h
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)2 [2 m4 P* w; L1 G8 n
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.. ?) N" O) |; b) f! w
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
6 N% @0 }: t! b" ?# Q r# r
|